Skip to main content

Table 1 Demographic and clinical characteristics of the participants in two groups

From: The relationship between severity of drug problems and perceived interdependence of drug use and sexual intercourse among adult males in drug addiction rehabilitation centers in Japan

 

perceived interdependence of sexual intercourse and drug use

  

weak groupa

strong groupb

Total

Analysis

n = 143

n = 297

n = 440

Statistic

p-value*

Age (median, Q1-Q3)

39

(32–46)

42

(36–48)

42

(34–47)

U = 24,555.000

0.008

Heterosexual: n (%)

127

(88.8)

251

(84.5)

378

(85.9)

 

0.245

Completed high school: n (%)

67

(46.9)

126

(42.4)

193

(43.9)

 

0.412

Unemployed: n (%)

111

(77.6)

214

(72.1)

325

(73.9)

 

0.247

Living condition: n (%)

 Living in a dormitory (rehabilitation center)

117

(81.8)

222

(74.7)

339

(77.0)

 

0.116

 Daycare

11

(7.7)

30

(10.1)

41

(9.3)

 

0.486

 Undergoing training as rehabilitation staff

15

(10.5)

45

(15.2)

60

(13.6)

 

0.235

Chronic disease (physical disease): n (%)

22

(15.4)

74

(25.2)

96

(22.0)

 

0.026

Primary drug: n (%)

 Methamphetamine

56

(39.2)

214

(72.1)

270

(61.4)

 

< 0.001

 NPS

22

(15.4)

38

(12.8)

60

(13.6)

 

0.461

 Organic solvent

14

(9.8)

12

(4.0)

26

(5.9)

 

0.029

 Marijuana

11

(7.7)

13

(4.4)

24

(5.5)

 

0.179

 Prescription drugs

17

(11.9)

7

(2.4)

24

(5.5)

 

< 0.001

 Over-the-counter drugs

14

(9.8)

6

(2.0)

20

(4.5)

 

0.001

 Others (cocaine, heroin, MDMA, gas)

9

(6.3)

7

(2.4)

16

(3.6)

 

0.055

Drug-related criminal history: n (%)

40

(28.0)

163

(54.9)

203

(46.1)

 

< 0.001

Never experienced treatment: n (%)

22

(15.5)

64

(21.8)

86

(19.7)

 

0.157

Consistent condom use under the influence of drugs: n (%)

 Always uses condoms

66

(46.2)

38

(12.8)

104

(23.7)

 

< 0.001

 Sometimes a non-condom user

27

(18.9)

50

(16.9)

77

(17.5)

 

0.595

 Mostly a non-condom user

50

(35.0)

208

(70.3)

258

(58.8)

 

< 0.001

Injecting and sharing needles during drug use: n (%)

 None

74

(52.9)

60

(20.5)

134

(31.0)

 

< 0.001

 Only experienced injection

16

(11.4)

46

(15.8)

62

(14.4)

 

0.245

 Experienced injection and sharing needles

50

(35.7)

186

(63.7)

236

(54.6)

 

< 0.001

Diagnosis of sexually transmitted disease in lifetime: n (%)

 Hepatitis A

0

(0.0)

1

(0.3)

1

(0.2)

 

1.000

 Hepatitis B

1

(0.7)

18

(6.3)

19

(4.5)

 

0.006

 Hepatitis C

19

(13.6)

92

(32.2)

111

(26.1)

 

< 0.001

 Gonorrhea

6

(4.3)

30

(10.5)

36

(8.5)

 

0.040

 Chlamydia

7

(5.0)

22

(7.7)

29

(6.8)

 

0.413

 Syphilis

2

(1.4)

19

(6.6)

21

(4.9)

 

0.017

 HIV

0

(0.0)

18

(6.3)

18

(4.2)

 

0.001

 Never diagnosis of STD

110

(78.6)

139

(48.6)

249

(58.5)

 

< 0.001

DAST-20 total score (median, Q1-Q3)

13.0

(10–16)

15.0

(12–17)

14.0

(12–16)

U = 25,873.500

< 0.001

  1. *p-value for Fisher’s exact test or Mann–Whitney U test
  2. Significant p-values are shown in bold type and underlined (p < 0.01)
  3. a Weak group consisted of respondents who considered the relationship between drug use and sexual intercourse was perceived “extremely weak + weak”
  4. b Strong group consisted of respondents who considered the relationship between drug use and sexual intercourse was perceived “extremely strong + strong”
  5. Abbreviations: NPS new psychoactive substances, MDMA 3, 4-methylenedioxymethamphetamine, STDs sexually transmitted diseases, HIV human immunodeficiency virus, DAST the Drug Abuse Screening Test